Literature DB >> 26309060

Combined melatonin and exendin-4 therapy preserves renal ultrastructural integrity after ischemia-reperfusion injury in the male rat.

Hon-Kan Yip1,2,3,4, Chih-Chao Yang5, Kuan-Hung Chen6, Tien-Hung Huang1, Yi-Ling Chen1, Yen-Yi Zhen1, Pei-Hsun Sung1, Hsin-Ju Chiang7, Jiunn-Jye Sheu8, Chia-Lo Chang9, Chih-Hung Chen10, Hsueh-Wen Chang11, Yen-Ta Chen12.   

Abstract

We tested whether combined melatonin (Mel) and exendin-4 (Ex4) treatment can better preserve glomerular structural integrity after ischemia-reperfusion (IR) injury compared with either alone. Adult male Sprague Dawley rats (n = 50) were equally divided into sham control (SC), IR, IR-Ex4 (10 μg/kg subcutaneously 30 min after reperfusion and daily for 5 days), IR-Mel (20 mg/kg intraperitoneally at 30 min postreperfusion and 50 mg/kg at 6 and 18 hr), and IR-Ex4-Mel were euthanized at day 14. Serum creatinine level and urine protein-to-creatinine ratio at days 3 and 14 were highest in IR group and lowest in SC, significantly higher in IR-Ex4 and IR-Mel groups than in IR-Ex4-Mel group (all P < 0.001) without significant difference between IR-Ex4 and IR-Mel groups. Changes in podocyte injury score (PIS) and kidney injury score were highest in IR group and lowest in SC, significantly higher in IR-Ex4 and IR-Mel groups than in IR-Ex4-Mel, and significantly higher in IR-Mel group than in IR-Ex4 group (all P < 0.001). Immunohistochemical microscopic findings of the expressions of FSP-1 and WT-1 (two glomerular damage indicators) and KIM-1 and snail (two renal tubular-damaged indicators) showed an identical pattern, whereas the expressions of ZO-1, p-cadherin, podocin, dystroglycan, fibronectin, and synaptopodin (six indices of glomerular integrity) demonstrated an opposite pattern compared to that of PIS among five groups (all P < 0.001). Protein expressions of inflammatory (TNF-α/NF-κB/MMP-9) and oxidative stress (NOX-1, NOX-2, oxidized protein) biomarkers exhibited an identical pattern to that of PIS among five groups (all P < 0.001). Combined melatonin-exednin-4 therapy further protected glomerulus from IR injury.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  exendin-4; ischemia-reperfusion; kidney ultrastructure; melatonin; podocyte

Mesh:

Substances:

Year:  2015        PMID: 26309060     DOI: 10.1111/jpi.12273

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  17 in total

1.  Impact of impaired cardiac function on the progression of chronic kidney disease---role of pharmacomodulation of valsartan.

Authors:  Chih-Chao Yang; Hon-Kan Yip; Kuan-Hung Chen; Cheuk-Kwan Sun; Yen-Ta Chen; Han-Tan Chai; Pei-Hsun Sung; Hsin-Ju Chiang; Sheung-Fat Ko; Sheng-Ying Chung; Chih-Hung Chen; Kun-Chen Lin; Pao-Yuan Lin; Jiunn-Jye Sheu
Journal:  Am J Transl Res       Date:  2017-05-15       Impact factor: 4.060

2.  Exendin-4-assisted adipose derived mesenchymal stem cell therapy protects renal function against co-existing acute kidney ischemia-reperfusion injury and severe sepsis syndrome in rat.

Authors:  Pei-Hsun Sung; Hsin-Ju Chiang; Christopher Glenn Wallace; Chih-Chao Yang; Yen-Ta Chen; Kuan-Hung Chen; Chih-Hung Chen; Pei-Lin Shao; Yung-Lung Chen; Sarah Chua; Han-Tan Chai; Yi-Ling Chen; Tien-Hung Huang; Hon-Kan Yip; Mel S Lee
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

3.  Combined therapy with melatonin and exendin-4 effectively attenuated the deterioration of renal function in rat cardiorenal syndrome.

Authors:  Kuan-Hung Chen; Chih-Hung Chen; Christopher Glenn Wallace; Yen-Ta Chen; Chih-Chao Yang; Pei-Hsun Sung; Hsin-Ju Chiang; Yi-Ling Chen; Sarah Chua; Hon-Kan Yip; Jiin-Tsuey Cheng
Journal:  Am J Transl Res       Date:  2017-02-15       Impact factor: 4.060

4.  Circulating microparticles enhanced rat vascular wall remodeling following endothelial denudation.

Authors:  Fan-Yen Lee; Hung-I Lu; Han-Tan Chai; Jiunn-Jye Sheu; Yi-Ling Chen; Tein-Hung Huang; Gour-Shenq Kao; Sheng-Yi Chen; Sheng-Ying Chung; Pei-Hsun Sung; Hsueh-Wen Chang; Mel S Lee; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2016-11-15       Impact factor: 4.060

Review 5.  Melatonin and mitochondrial function during ischemia/reperfusion injury.

Authors:  Zhiqiang Ma; Zhenlong Xin; Wencheng Di; Xiaolong Yan; Xiaofei Li; Russel J Reiter; Yang Yang
Journal:  Cell Mol Life Sci       Date:  2017-08-09       Impact factor: 9.261

6.  Inhibition of histone methyltransferase G9a effectively protected the kidney against ischemia-reperfusion injury.

Authors:  Peihsun Sung; Chihchao Yang; John Y Chiang; Chihhung Chen; Chiwen Luo; Honkan Yip
Journal:  Am J Transl Res       Date:  2022-06-15       Impact factor: 3.940

7.  Extendin-4 protects kidney from acute ischemia-reperfusion injury through upregulation of NRF2 signaling.

Authors:  Yen-Yi Zhen; Chih-Chao Yang; Chi-Chih Hung; Chia-Chang Lee; Chen-Chang Lee; Chien-Hsing Wu; Yen-Ta Chen; Wei-Yu Chen; Kuan-Hung Chen; Hon-Kan Yip; Sheung-Fat Ko
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

8.  Combination therapy with extracorporeal shock wave and melatonin markedly attenuated neuropathic pain in rat.

Authors:  Kuan-Hung Chen; Chien-Hui Yang; Christopher Glenn Wallace; Chung-Ren Lin; Chia-Kai Liu; Tsung-Cheng Yin; Tien-Hung Huang; Yi-Ling Chen; Cheuk-Kwan Sun; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2017-10-15       Impact factor: 4.060

9.  Short- and Long-Term Protective Effects of Melatonin in a Mouse Model of Sepsis-Associated Encephalopathy.

Authors:  Mu-Huo Ji; De-Guo Xia; Lan-Yue Zhu; Xia Zhu; Xiao-Yan Zhou; Jiang-Yan Xia; Jian-Jun Yang
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

10.  Combination therapy of exendin-4 and allogenic adipose-derived mesenchymal stem cell preserved renal function in a chronic kidney disease and sepsis syndrome setting in rats.

Authors:  Chih-Hung Chen; Ben-Chung Cheng; Kuan-Hung Chen; Pei-Lin Shao; Pei-Hsun Sung; Hsin-Ju Chiang; Chih-Chao Yang; Kun-Chen Lin; Cheuk-Kwan Sun; Jiunn-Jye Sheu; Hsueh-Wen Chang; Mel S Lee; Hon-Kan Yip
Journal:  Oncotarget       Date:  2017-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.